Home > Waters & Kraus, LLP > Legal Library

Legal Articles: Waters & Kraus, LLP

 







Document(s) published by this organization: 45


View Page: 1  2  3  4  5  Next  
Show: results per page
Sort by:

HTMLF.B.I. Investigates Power Morcellator Injuries
Waters Kraus LLP;
Legal Alert/Article
June 25, 2015, previously published on June 22, 2015
June 22, 2015 - The Federal Bureau of Investigation (F.B.I.) reportedly has launched an investigation into whether laws were broken by medical device manufacturers of the power morcellator device. Used in gynecologic surgery to perform hysterectomies and remove fibroid tumors, the power morcellator...

 

HTMLStandard Chemotherapy Regimen for Pleural Mesothelioma May Add Bevacizumab
Peter A. Kraus, Troyce G. Wolf; Waters & Kraus, LLP;
Legal Alert/Article
June 24, 2015, previously published on June 17, 2015
Malignant pleural mesothelioma may soon be getting a new standard of care. Bevacizumab may be added to the current standard chemotherapy regimen of pemetrexed and cisplatin. According to Dr. Gerald Zalcman, who recently presented a paper at the 2015 American Society of Clinical Oncology (ASCO)...

 

HTMLMethod Discovered to Remove Benzene from Gasoline
Waters Kraus LLP;
Legal Alert/Article
June 24, 2015, previously published on June 15, 2015
Benzene exposure is a particular concern for those who work around gasoline and crude oil, both of which contain the dangerous substance. In fact, the U.S. Energy Information Administration estimates that Americans used 137 billion gallons of gasoline last year.

 

HTMLCalifornia Lawsuit Filed on Behalf Of 12 Injured by Xarelto
Waters Kraus LLP;
Legal Alert/Article
June 18, 2015, previously published on April 22, 2015
Bayer Corp. and Janssen Pharmaceuticals Inc. (a unit of Johnson & Johnson) have been sued in a California lawsuit by 12 people injured from using the companies’ blood thinner Xarelto. The plaintiffs who filed the California lawsuit were taking Xarelto to treat atrial fibrillation or to...

 

HTMLMesothelioma Treatments May Include New Immunotherapy Drug
Waters Kraus LLP;
Legal Alert/Article
June 18, 2015, previously published on April 20, 2015
The benefit of immunotherapy for mesothelioma patients is that the treatment uses the body’s own immune system to attack mesothelioma cells without causing injury to healthy cells nearby. In a recently published study of tremelimumab, Italian researchers from the University Hospital of Siena...

 

HTMLScientists Map Genome for Peritoneal Mesothelioma
Waters Kraus LLP;
Legal Alert/Article
June 18, 2015, previously published on April 13, 2015
Scientists searching for effective treatments for peritoneal mesothelioma are excited about the recent mapping of the genome sequence for the disease. Peritoneal mesothelioma is a fatal cancer of the lining surrounding the abdominal organs. The only confirmed cause of the disease is asbestos...

 

HTMLBritish Patients Also Suffering From Dangerous Metal Hip Device
Waters Kraus LLP;
Legal Alert/Article
June 18, 2015, previously published on April 17, 2015
Patients in the United Kingdom are experiencing the same problems with metal-on-metal hip replacements that those here in the United States are suffering. The manufacturers of one defective metal hip device called the ‘Birmingham Hip Modular Head total hip replacement’ (BHMH) have...

 

HTMLTransvaginal Mesh Lawsuits to Remain in Pennsylvania
Waters Kraus LLP;
Legal Alert/Article
June 18, 2015, previously published on April 15, 2015
Johnson & Johnson and Boston Scientific Corp. — two manufacturers of vaginal mesh implants that have caused injuries to many women across the nation — have lost their bid to toss almost 100 transvaginal mesh cases out of court in Pennsylvania.

 

HTMLDefactnib Shrinks Size of Mesothelioma Tumors
Waters Kraus LLP;
Legal Alert/Article
June 17, 2015, previously published on May 18, 2015
A clinical trial focused on finding an effective treatment for mesothelioma reportedly is showing encouraging results. The clinical trial involves Defactnib (VS-6063), an Oral Focal Adhesion Kinase Inhibitor developed by the drug maker Verastem, Inc.

 

HTMLAggressive Mesothelioma Surgery Improves Quality of Life for Many
Waters Kraus LLP;
Legal Alert/Article
June 17, 2015, previously published on May 4, 2015
A recent study from the University of Chicago Medical Center’s Oncology Division of the Department of Surgery reports that mesothelioma patients undergoing aggressive pleurectomy/decortication surgery experience different results, depending on the progression of their disease.

 


View Page: 1  2  3  4  5  Next